MedWatch

Oticon Medical General Manager after US FDA approval: It's a competitive situation

Demant's bone-anchored division Oticon Medical will be put to the test when establishing itself on the US market for cochlear implants following the FDA approval last week. Competing companies are far ahead, and the Danish firm still has gaps to close in its product range, according to General Manager Jes Olsen.

On Thursday last week, Demant's bone-anchored division was delighted to announce that the US Food and Drug Administration (FDA) has given the necessary authorization for the Danish hearing company to sell and market its cochlear implant system Neuro 2 on what is unconditionally the largest market in the world.

"This is huge for us. Perhaps the largest milestone in the history of Oticon. I cannot stress enough how significant it is that we can enter the US with out Neuro 2 implant system – a game changer, is what I'd call it," Oticon Medical General Manager Jes Olsen told MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs